AI
20/20 Biolabs Inc.
AIDX · NASDAQ
$0.38 -1.06% (-$0.00)
1M -27.95%
Market Cap $4.59M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.42
12.0% upside
Current Price
$0.38
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AIDX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
71 /100
Cheap P/S 2.25x
EV/EBITDA N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 43.03%
FCF growth N/A
Book val. growth N/A
Profitability
11 /100
Weak Net margin 182.82%
Op. margin 162.87%
FCF margin 93,867.70%
Quality
2 /100
Poor ROA 0.09%
Asset turnover 0.00x
ROIC 0.26%
Debt
5 /100
High Int. coverage 0.02x
Current ratio 0.60x
Net debt/EBITDA N/A
Stability
8 /100
Unstable Rev. volatility 61.85%
EPS volatility 412.29%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AIDX
Online
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Jonathan Cohen
Employees
14
Headquarters
Gaithersburg